RBT-1 reduces blood product utilization in patients undergoing nonemergency coronary artery bypass grafting and/or valve surgeryCentral Message

• Charles A. Mack, MD,
• Michael Jessen, MD,
• Andre Lamy, MD,
• Ashish K. Khanna, MD,
• Kevin Lobdell, MD,
• Rakesh Arora, MD,
• Jeannette Rodriguez, PhD,
• Stacey Ruiz, PhD,
• Bhupinder Singh, MD

Affiliations

Charles A. Mack, MD

Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY; Address for reprints: Charles A. Mack, MD, Department of Cardiothoracic Surgery, Weill Cornell Medicine, 525 E 68th St, M-404, New York, NY 10065.

Michael Jessen, MD

Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern, Dallas, Tex

Andre Lamy, MD

Department of Perioperative Medicine and Surgery, Population Health Research Institute, Hamilton, Ontario, Canada

Ashish K. Khanna, MD

Perioperative Outcomes and Informatics Collaborative, Section on Critical Care Medicine, Department of Anesthesiology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC; Outcomes Research Consortium, Cleveland, Ohio

Kevin Lobdell, MD

Sanger Heart and Vascular Institute, Atrium Health, Charlotte, NC

Rakesh Arora, MD

Division of Cardiac Surgery, Department of Surgery, Harrington Heart and Vascular Institute, University Hospitals–Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio

Jeannette Rodriguez, PhD

Department of Drug Development, Renibus Therapeutics, Inc, Southlake, Tex

Stacey Ruiz, PhD

Department of Drug Development, Renibus Therapeutics, Inc, Southlake, Tex

Bhupinder Singh, MD

Medical Office, Renibus Therapeutics, Inc, Southlake, Tex